265 related articles for article (PubMed ID: 30962222)
1. Targeting CD47 in Sézary syndrome with SIRPαFc.
Johnson LDS; Banerjee S; Kruglov O; Viller NN; Horwitz SM; Lesokhin A; Zain J; Querfeld C; Chen R; Okada C; Sawas A; O'Connor OA; Sievers EL; Shou Y; Uger RA; Wong M; Akilov OE
Blood Adv; 2019 Apr; 3(7):1145-1153. PubMed ID: 30962222
[TBL] [Abstract][Full Text] [Related]
2. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
3. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
4. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
[TBL] [Abstract][Full Text] [Related]
5. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
Xiao A; Akilov OE
Cells; 2022 Nov; 11(22):. PubMed ID: 36429020
[TBL] [Abstract][Full Text] [Related]
6. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
8. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the CD47-SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome.
Stadler R
Lancet Haematol; 2021 Nov; 8(11):e779-e781. PubMed ID: 34627594
[No Abstract] [Full Text] [Related]
10. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
11. A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer.
Liu J; Meng Z; Xu T; Kuerban K; Wang S; Zhang X; Fan J; Ju D; Tian W; Huang X; Huang X; Pan D; Chen H; Zhao W; Ye L
Front Immunol; 2022; 13():845217. PubMed ID: 35422796
[TBL] [Abstract][Full Text] [Related]
12. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
13. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
14. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778
[TBL] [Abstract][Full Text] [Related]
17. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC; Shi W; Shi JJ; Lu JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
[TBL] [Abstract][Full Text] [Related]
18. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
19. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.
Folkes AS; Feng M; Zain JM; Abdulla F; Rosen ST; Querfeld C
Curr Opin Oncol; 2018 Sep; 30(5):332-337. PubMed ID: 29994903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]